B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
Morrow
David A
DA
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: dmorrow@partners.org.
Scirica
Benjamin M
BM
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Sabatine
Marc S
MS
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
de Lemos
James A
JA
University of Texas Southwestern Medical School, Dallas, Texas.
Murphy
Sabina A
SA
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jarolim
Petr
P
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Theroux
Pierre
P
Montreal Heart Institute, Montreal, Quebec, Canada.
Bode
Christophe
C
Medizinische Universitatsklinik, University of Freiburg, Freiburg, Germany.
Braunwald
Eugene
E
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
D000083:Acetanilides / Q000494:pharmacology*; D054058:Acute Coronary Syndrome / Q000175:diagnosis* / Q000188:drug therapy*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010879:Piperazines / Q000494:pharmacology*; D000069458:Ranolazine; D012307:Risk Factors
D000083:Acetanilides; D015415:Biomarkers; D004791:Enzyme Inhibitors; D010879:Piperazines; D020097:Natriuretic Peptide, Brain; D000069458:Ranolazine